

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-15** | Period of Report: **2013-01-14**
SEC Accession No. [0001104659-13-002566](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

CALLISTO PHARMACEUTICALS INC

CIK: **1142380** | IRS No.: **651107840** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **001-32325** | Film No.: **13529509**
SIC: **2834** Pharmaceutical preparations

Mailing Address
420 LEXINGTON AVENUE
SUITE 601
NEW YORK NY 10170

Business Address
420 LEXINGTON AVENUE
SUITE 601
NEW YORK NY 10170
2126729190

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 14, 2013**

Callisto Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-32325
(Commission
File Number)

33-3894575
(I.R.S. Employer
Identification No.)

420 Lexington Avenue, Suite 1609
New York, NY
(Address of principal executive offices)

10170
(Zip code)

(212) 297-0010
(Registrant's telephone number including area code)

N/A
(Former name and former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The reconvened Special Meeting of Stockholders of Callisto Pharmaceuticals, Inc. ("Callisto") was held on January 14, 2013. At the Special Meeting of Stockholders, the stockholders of Callisto approved and adopted the Agreement and Plan of Merger dated as of July 20, 2012, as amended on October 15, 2012, by and between Callisto and Synergy Pharmaceuticals Inc. ("Synergy"), pursuant to which Callisto will merge with and into Synergy, based on the votes listed below:

For	Withheld/Against	Abstain	Broker Non- Votes
103,640,681	136,141	29,120	0

A copy of the press release announcing the results of the Special Meeting is attached hereto as exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this Current Report on Form 8-K:

(d) Exhibits.

99.1 Press Release dated January 15, 2013

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CALLISTO PHARMACEUTICALS, INC.

Date: January 15, 2013

By: /s/ Gary S. Jacob

Name: Gary S. Jacob, PhD

Title: Chief Executive Officer

3

**Callisto Stockholders Approve Merger with Synergy
Pharmaceuticals**

NEW YORK, N.Y., January 15, 2013 – Callisto Pharmaceuticals, Inc. (OTC QB:CLSP) (“Callisto”) today announced that it convened its special meeting of stockholders yesterday and it has received the necessary approvals from its stockholders to authorize Callisto’s merger with and into Synergy Pharmaceuticals Inc. (“Synergy”) pursuant to the previously announced Agreement and Plan of Merger, dated July 20, 2012, as amended on October 15, 2012. Callisto and Synergy expect to close the merger as soon as practicable.

About Callisto Pharmaceuticals Inc.

Callisto is a development stage biopharmaceutical company. All of Callisto’s drug candidates, currently plecanatide and SP-333 to treat GI disorders and diseases, are being developed exclusively by Synergy.

Investor Contact: Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
